Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biomarin Pharmaceuticals (NQ: BMRN ) 70.58 +0.34 (+0.48%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Biomarin Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 Next > Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced. September 26, 2024 Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability. Via Chartmill BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish September 25, 2024 BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139... Via Benzinga Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents. September 25, 2024 BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), an undervalued stock with good fundamentals. Via Chartmill If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today September 23, 2024 Via Benzinga Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? September 22, 2024 10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% Via Benzinga (BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest September 10, 2024 Via Benzinga (BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest August 21, 2024 Via Benzinga Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock August 20, 2024 Via Benzinga GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday September 17, 2024 Via Benzinga Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term September 16, 2024 BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits. Via Benzinga Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug September 16, 2024 The companies could soon face off in the growth treatment market for children with a genetic disorder. Via Investor's Business Daily FDA Battles Backlog of Drug Factory Inspections Since COVID-19 September 06, 2024 FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. Via Benzinga Exposures Product Safety BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027 September 05, 2024 BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enhance growth. Via Benzinga Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN. July 24, 2024 BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock which is not overvalued. Via Chartmill $1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today July 16, 2024 Via Benzinga Peering Into Biomarin Pharmaceutical's Recent Short Interest July 04, 2024 Via Benzinga Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings) September 05, 2024 Via Benzinga Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In September 04, 2024 Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... Via Benzinga NASDAQ:BMRN is showing good growth, while it is not too expensive. September 04, 2024 Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced. Via Chartmill Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24 August 24, 2024 What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Aug. 19-23, 2024. Via Talk Markets Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday August 20, 2024 Via Benzinga NASDAQ:BMRN is not too expensive for the growth it is showing. August 14, 2024 While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable. Via Chartmill $1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today August 07, 2024 Via Benzinga Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance August 06, 2024 BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost reductions aim to achieve profitability by 2025. Strong Q2 performance driven... Via Benzinga Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday August 06, 2024 Via Benzinga Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results August 06, 2024 Via Benzinga BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Beats Revenue for Q2 2024 August 05, 2024 BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts July 22, 2024 Via Benzinga $100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today July 18, 2024 Via Benzinga Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced. July 02, 2024 Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced. Via Chartmill < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.